Possible availability of N-acetylcysteine as an adjunct to cytokine therapy for hepatocellular carcinoma

Clinical Immunology and Immunopathology

Volumn 88, Issue 2, 1998, Pages 192-198

  Tsuyuki, Shigeru ^a   Yamauchi, Akira ^a   Nakamura, Hajime ^a   Kinoshita, Koichi ^a   Gomi, Takashi ^a   Tanaka, Koichi ^a   Inamoto, Takashi ^a   Yamaoka, Yoshio ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Cytotoxic activity; Glutathione; Hepatocellular carcinoma; Liver associated mononuclear cells

Indexed keywords

ACETYLCYSTEINE; CYTOKINE;

ADULT; ARTICLE; CELLULAR DISTRIBUTION; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFECT; FEMALE; HUMAN; LIVER CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; SURGICAL STRESS;

EID: 0031660054     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1998.4574     Document Type: Article

References (43)

1. Harata, I., Yamauchi, K., Aruga, A., Komatsu, T., Takasaki, K., Hayashi, N., and Hanyu, F., Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: Comparison between LAK cell and CTL therapy. J. Immunother. 19, 218-223, 1996.
2. Yamamoto, M., and Fujii, H., Optimal locoregional immunochemotherapy after tumor-mass reduction for advanced hepatocellular carcinoma. Hepatogastroenterology 42, 567-577, 1995.
3. Kanai, M., Inamoto, T., Kinoshita, K., and Yamaoka, Y., Phenotypic analysis and natural killer activity of human sinusoidal mononuclear cells. In "Current Topics in Mucosal Immunology 1993" (M. Tsuchiya, et al. Eds.), pp. 253-256, Elsevier, Amsterdam, 1993.
4. Kanai, M., Inamoto, T., Kanaya, S., Kinoshita, K., Fujimura, N., and Yamauchi, A., Inhibition of epidermal growth factor-stimulated hepatocytes proliferation by autologous sinusoidal mononuclear cells in rat liver. Clin. Immunol. Immunopathol. 69, 23-28, 1993.
5. Johnkoski, J. A., Tzung, S. P., Doerr, R. J., and Cohen, S. A., Hepatic metastasis alters the immune function of murine liver nonparenchymal cells. Arch. Surg. 127, 1325-1329, 1992.
6. Oka, M., Hazada, S., Suzuki, M., Wang, F., Shimoda, K., Iizuka, N., Wadamori, K., Suzuki, T., and Attwood, S., Depression of cytotoxicity of nonparenchymal cells in liver after surgery. Surgery 116, 877-882, 1994.
7. Vujanovic, N. L., Polimeno, L., Azzarone, A., Francavilla, A., Chambers, W. H., Starzl, T. E., Herberman, R. B., and Whiteside, T. H., Changes of liver-resistant NK cells during liver regeneration in rats. J. Immunol. 154, 6324-6338, 1995.
8. Yamauchi, A., and Bloom, E. T., Requirement of thiol compounds as reducing agents for IL-2-mediated induction of LAK activity and proliferation of human NK cells. J. Immunol. 151, 5535-5544, 1993.
9. Shigesawa, T., Sato, C., and Marumo, F., Significance of plasma glutathione determination in patients with alcoholic and non-alcoholic liver disease. J. Gastroenterol. Hepatol. 7, 7-11, 1992.
10. Altomare, E., Vendemiale, G., and Albano, O., Hepatic glutathione content in patients with alcoholic and nonalcoholic liver diseases. Life Sci. 43, 991-998, 1988.
11. Engin, A., and Ferahköse, Z., Liver glutathione contents in patients with gastric adenocarcinomas. Tumori 76, 48-50, 1990.
12. Blumberg, D., Hochwald, S., Pinto, J., and Burt, M., Altered glutathione metabolism in tumor-bearing state. Ann. Surg. Oncol. 2, 332-335, 1995.
13. Bloom, E. T., and Korn, E. L., Quantification of natural cytotoxicity by human lymphocyte subpopulations isolated by density: Heterogeneity of the effector cells. J. Immunol. Methods 58, 323-335, 1983.
14. Tietze, F., Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Applications to mammalian blood and other tissues. Anal. Biochem. 27, 502-522, 1969.
15. Anderson, M. E., Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol. 113, 548-555, 1985.
16. Bloom, E. T., Natural killer cells, lymphokine-activated killer cells, and cytolytic T lymphocytes: Compartmentalization of age-related changes in cytolytic lymphocytes? J. Gerontol. 49, B85-B92, 1994.
17. Tsukahara, A., Seki, S., Iiai, T., Morota, T., Watanabe, H., Suzuki, S., Tada, T., Hiraide, H., Hatakeyama, K., and Abo, T., Mouse liver T cells: Their change with aging and in comparison with peripheral T cells. Hepatology 26, 301-309, 1997.
18. Hirofuji, H., Kakumu, S., Fuji, A., Ohtani, Y., Murase, K., and Tahara, H., Natural killer and activited killer activities in chronic liver disease and hepatocellular carcinoma: Evidence for a decreased lymphokine-induced activity of effector cells. Clin. Exp. Immunol. 68, 348-356, 1987.
19. Shirai, M., Watanabe, S., and Nishioka, M., Defective immunological fuctions associated with abnormal lymphokine-activated killer activity in patients with hepatocellular carcinoma. J. Gastroenterol. Hepatol. 5, 542-548, 1990.
20. Shirai, M., Watanabe, S., and Nishioka, M., Intratumoral injection of OK432 and lymphokine-activated killer activity in peripheral blood of patients with hepatocellular carcinoma. Eur. J. Cancer. 26, 965-969, 1990.
21. Schwarz, R., Iwatsuki, S., Herberman, R. B., and Whiteside, T. L., Lymphokine-activated killer cells in patients with primary and metastatic malignant liver tumors. Hepatology 10, 221-227, 1989.
22. Brookes, R. H., Kew, M. C., and Rabson, A. R., Depressed natural cytotoxicity but normal natural killer cytotoxicity factor (NKCF) production by mononuclear cells derived from patients with hepatocellular carcinoma. Cancer Immunol. Immunother. 25, 149, 1987.
23. Winnock, M., Garcia-Barcina, M., Huet, S., Bernard, P., Saric, J., Bioulac-Sage, P., Gualde, N., and Balabaud, C., Functional characterization of liver-associated lymphocytes in patients with liver metastasis. Gastroenterology 105, 1152-1158, 1993.
24. Hata, K., Van Ronald, D. H., Herberman, R. B., and Whiteside, T. L., Natural killer activity of liver-derived lymphocytes in various liver diseases. Hepatology 14, 496-503, 1991.
25. Smyth, M. J., Glutathione modulates activation dependent proliferation of human peripheral blood lymphocyte populations without regulating their activated function. J. Immunol. 146, 1921-1927, 1991.
26. Droge, W., Schulze-osthoff, K., Mihm, S., Galter, D., Schenk, H., Eck, H. P., Roth, S., and Gmünder, H., Function of glutathione and glutathione disulfide in immunology and immunopathology. FASEB J. 8, 1131-1138, 1994.
27. Droge, W., Cysteine and glutathione deficiency in AIDS patients: A rationale for the treatment with N-acetyl-cysteine. Pharmacology 46, 61-65, 1993.
28. Droge, W., Eck, H. P., and Mihm, S., HIV-induced cysteine deficiency and T-cell dysfunction - A rationale for treatment with N-acetylcysteine. Immunol. Today 13, 211-214, 1992.
29. Buhl, R., Jaffe, H. A., Holroyd, K. J., Wells, F. B., Mastrangeli, A., Saltini, C., Cantin, M., and Crystal, R. G., Systemic glutathione deficiency in symptom free seropositive individuals. Lancet 2, 1294-1298, 1989.
30. Bedossa, P., Peltier, E., Terris, B., Franco, D., and Poynard, T., Transforming growth factor-β1 (TGF-β1) and TGF-β1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 21, 760, 1995.
31. Shirai, Y., Kawata, S., Tamura, S., Ito, N., Tsushima, H., Takaishi, K., Kiso, S., and Matsuzawa, Y., Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 73, 2275-2279, 1994.
32. Logie, S. A., Quigly, E. M., MacSween, R. N., and Sandilands, G. P., Serum mediated inhibition of T-cell activation in primary biliary cirrhosis. J. Clin. Lab. Immunol. 9, 81-85, 1982.
33. Corrocher, R., Casaril, M., Bellisola, G., Gabrielli, G. B., Nicoli, N., Guidi, G. C., and De Sandre, G., Severe impairment of anti-oxidant system in human hepatoma. Cancer 58, 1658-1662, 1986.
34. Casaril, M., Corso, F., Capra, F., Gabrielli, G. B., Stanzial, A. M., Nicoli, N., and Corrocher, R., Decreased activity of scavenger emzymes in human hepatocellular carcinoma, but not in liver metastases. Int. Clin. Lab. Res. 24, 94-97, 1994.
35. Sherman, M., Campbell, A. H., Titmuss, S. A., Kew, M. C., and Kirsch, R. E., Glutathione S-transferase in human hepatocellular carcinoma. Hepatology 3, 170-176, 1983.
36. Zhou, T., Evans, A. A., Thomas London, W., Xia, X., Zou, X., Shen, Fu-min, and Clapper, M. L., Glutathione S-transferase expression in hepatitis B virus B virus-associated human hepatocellular carcinogenesis. Cancer Res. 57, 2749-2753, 1997.
37. Herzenberg, L. A., De Rosa, S. C., Dubs, J. G., Roederer, M., Anderson, M. T., Ela, S. W., Deresinski, S. C., and Herzenberg, L. A., Glutathione deficiency is associated with impaired sur-vival in HIV disease. Proc. Natl. Acad. Sci. USA 94, 1967-1972, 1997.
38. Otsuji, M., Kimura, Y., Aoe, T., Okamoto, Y., and Saito, T., Oxidative stress by tumor-derived macrophages suppresses the expression of CDζ chain of T-cell receptor complex and antigen-specific T-cell responses. Proc. Natl. Acad. Sci. USA 93, 13119-13124, 1996.
39. Yim, C. Y., Hibbs, J. B., Jr., McGregor, J. R., Galinsky, R. E., and Samlowski, W. E., Use of N-acetyl cysteine to increase intracellular glutathione during the induction of antitumor responses by IL-2. J. Immunol. 152, 5796-5805, 1994.
40. Malorni, W., D' Ambrosio, A., Rainaldi, G., Rivabene, R., and Viora, M., Thiol supplier N-acetylcysteine enhances conjugate formation between natural killer cells and K562 or U937 targets but increases the lytic function only against the latter. Immunol. Lett. 43, 209-214, 1994.
41. Devlin, J., Ellis, A. E., McPeake, J., Heaton, N., Wendon, J. A., Williams, R., N-Acetylcysteine improves indocyanine green extraction and oxygen transport during hepatic dysfuction. Crit. Care Med. 25, 236-242, 1997.
42. Jones, A. L., Javie, D. R., Simpson, D., Hayes, P. C., and Prescott, L. F., Pharmacokinetics of N-acetylcysteine are altered in patients with chronic liver disease. Aliment. Pharmacol. Ther. 11, 787-791, 1997.
43. Dalhoff, K., Ranek, L., Mantoni, M., and Poulson, H. E., Glutathione treatment of hepatocellular carcinoma. Liver 12, 341-345, 1992.